Category Archives: FDA Policy

CBD and FDA – Where Are We?

Last week FDA and FTC jointly issued a warning letter to a seller of CBD products in Florida – the seventh such warning letter of the year. The letter took issue with the manufactuer’s marketing practices related to multiple products … Continue reading

Posted in CBD, FDA Policy | Comments Off on CBD and FDA – Where Are We?

FDA Sends CBD Related Warning Letter

This week FDA sent a Warning Letter to a company engaged in marketing products containing cannabidiol (CBD) to consumers for a wide variety of uses in both humans and canines. In addition to the letter, the agency underscored their action … Continue reading

Posted in CBD, FDA Policy, Warning Letters | Comments Off on FDA Sends CBD Related Warning Letter

New Drug Approvals – A Mid-Year Assessment

During the past few years, there has been a renewed focus on facilitating the development of new medicines by providing new mechanisms to streamline the review process and get drugs to patients more quickly. The passage of the 21st Century … Continue reading

Posted in FDA, FDA Policy | Comments Off on New Drug Approvals – A Mid-Year Assessment

OPDP Sends Third Enforcement Letter of the Year

The folks at the Office of Prescription Drug Promotion (OPDP) have been in the mood lately to make a point. You can tell because they recently issued the third regulatory action letter of the year. Many years ago this would … Continue reading

Posted in FDA Policy, Warning Letters | Comments Off on OPDP Sends Third Enforcement Letter of the Year

OPDP Takes Second Enforcement Action of the Year

This week FDA’s Office of Prescription Drug Promotion (OPDP) posted what was only the second enforcement letter of the year which was issued in May. Warning letters are issued by many parts of the FDA, but OPDP issues letters squarely … Continue reading

Posted in FDA Policy, Warning Letters | Comments Off on OPDP Takes Second Enforcement Action of the Year